Related Experiment Videos
[Clinical evaluation of meropenem in children]
N Fukushima1, A Ishikawa, A Takase
1Department of Pediatrics, Sapporo City General Hospital.
Abstract:
Meropenem (MEPM) was evaluated for its efficacy and safety. The following results were obtained. MEPM was given to 12 patients with infections: 5 with pneumonia, 1 with bacterial meningitis, 2 with pharyngitis, 4 with skin and soft tissue infections. Therapeutic responses were "excellent" in 5, "good" in 4 and "fair" in 3, with an efficacy rate of 75%. Adverse reactions were not noted. No abnormalities were shown in laboratory data. It has been concluded that MEPM is a useful drug for the treatment of bacterial infections in children.
Insights
Meropenem (MEPM) demonstrated significant efficacy in treating pediatric bacterial infections, with a 75% success rate. This antibiotic showed a favorable safety profile, with no adverse reactions or laboratory abnormalities observed in the study group.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Therapeutics
Background:
- Bacterial infections pose a significant health challenge in pediatric populations.
- Effective and safe antibiotic options are crucial for managing childhood infections.
- Meropenem is a broad-spectrum carbapenem antibiotic with established utility.
Purpose of the Study:
- To evaluate the efficacy and safety of Meropenem (MEPM) in treating various bacterial infections in children.
- To determine the therapeutic response rates and identify any adverse events associated with MEPM use.
Main Methods:
- A cohort of 12 pediatric patients with diagnosed bacterial infections received Meropenem.
- Infections treated included pneumonia, bacterial meningitis, pharyngitis, and skin/soft tissue infections.
- Therapeutic responses were categorized as excellent, good, or fair, and adverse reactions were monitored.
Main Results:
- Meropenem was administered to 12 children across different infection types.
- An overall efficacy rate of 75% was achieved, with 5 patients showing an "excellent" response, 4 "good," and 3 "fair."
- No adverse reactions were reported, and laboratory data remained normal throughout the study.
Conclusions:
- Meropenem is a safe and effective treatment option for bacterial infections in pediatric patients.
- The drug exhibited a high therapeutic response rate with a favorable safety profile.
- Further research may explore Meropenem's role in specific pediatric infectious disease contexts.